Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology · Autoimmune Brainstem Encephalitis

Standard Treatments for Brainstem Encephalitis

At a Glance

Even without characteristic antibodies, autoimmune brainstem encephalitis may need prompt treatment after dangerous infections are assessed. First-line options include high-dose steroids, IVIG, or plasma exchange; severe cases may need rituximab or cyclophosphamide followed by a monitored steroid taper.

When your doctor suspects autoimmune brainstem encephalitis, time is of the essence. Because the brainstem controls vital functions like breathing and swallowing, medical teams often begin treatment empirically—meaning they start therapy based on your symptoms and clinical picture before all test results, such as rare antibody panels, have returned [1][2].

Research shows that starting treatment early is associated with much better long-term recovery [3][4]. Waiting for a “perfect” test result can allow inflammation to cause more damage. However, because immunosuppression can worsen an active infection, clinicians must first reasonably evaluate or cover for dangerous infections, often coordinating with infectious disease specialists [2].

What Happens in the Hospital

Severe brainstem disease requires comprehensive care that goes beyond just immune medications.

  1. Initial Stabilization: Ensuring your airway and swallowing are safe. This may involve an ICU stay, fall precautions, and a speech-language pathologist evaluation (like FEES or videofluoroscopic testing) to prevent aspiration.
  2. Diagnostic Sampling: Collecting CSF and blood for testing, ideally before immune therapies begin.
  3. Infection Management: Starting empiric antimicrobial treatment while testing is pending, if indicated.
  4. First-Line Immunotherapy: Initiating immune-calming therapies once an autoimmune cause is strongly suspected.

First-Line Therapies: Calming the Storm

The first goal of treatment is to quickly reduce inflammation. This usually involves one or more of the following “first-line” treatments [5][6]:

  • High-Dose Steroids: Doctors typically use intravenous (IV) methylprednisolone, often given daily for 3 to 5 days, though dosing is individualized. These act broadly to rapidly reduce inflammation [5][7].
  • IVIG (Intravenous Immunoglobulin): This is a collection of healthy antibodies from blood donors. When infused, it helps modulate the immune system. A common example regimen is 0.4 g/kg per day for 5 days [8][9].
  • Plasmapheresis (Plasma Exchange or PLEX): This process involves filtering your blood through a machine to physically remove inflammatory proteins and circulating antibodies [10][11].

In severe cases, doctors may use a combination of these treatments. However, sequencing matters greatly. For example, plasma exchange can remove recently administered IVIG, so they are not given simultaneously [1][12].

Second-Line Therapies: Targeted Suppression

If first-line treatments do not show enough improvement, or if symptoms are very severe, doctors may consider “escalating” to second-line therapies, though their benefit in seronegative disease requires individualized judgment [13][14]:

  • Rituximab: This medication depletes B-cells, the immune cells responsible for producing antibodies. However, it does not eliminate all antibody-producing plasma cells or T-cell-driven inflammation [13][15].
  • Cyclophosphamide: A stronger immunosuppressant sometimes considered in refractory cases [13][6].

The “Bridge” to Recovery

After the intense IV treatments in the hospital, most patients transition to an oral steroid taper (like Prednisone). This “bridge” therapy slowly lowers your dose over several weeks or months to prevent the inflammation from rebounding [5][16]. Never stop your steroids abruptly or change your dose without your doctor’s explicit instructions.

Risks and Monitoring

While these treatments are life-saving, they carry risks that your team will monitor closely [17]:

Treatment Common Risks/Side Effects Required Monitoring
Steroids High blood sugar, severe mood or psychiatric changes, insomnia, osteoporosis, increased infection risk [7][18]. Blood pressure, blood glucose, bone density (long-term), and mental health [19].
IVIG Headaches, infusion reactions, aseptic meningitis, and rare blood clots [8][9]. Kidney function and hydration status.
Plasma Exchange Low blood pressure, electrolyte imbalances, bleeding risks, and catheter-related infections [10][20]. Heart rate, blood pressure, and calcium levels during the procedure.
Rituximab Infusion reactions and increased risk of serious infections (hypogammaglobulinemia) [21][22]. White blood cell counts and screening for dormant infections (like Hepatitis B) before starting [23].

Your team will use functional clinical scales (like checking your swallowing or balance) to decide when it is safe to adjust your treatment intensity. While follow-up MRIs may be ordered, they can sometimes lag behind your clinical improvement and are not the sole factor in decision-making [1][4].

Common questions in this guide

Why do doctors sometimes begin treatment before antibody tests are finished?
The brainstem controls breathing and swallowing, so untreated inflammation can become dangerous. Doctors may start immune treatment based on symptoms and examination after they have reasonably evaluated for serious infections or begun appropriate infection coverage. A negative or pending antibody test does not always rule out autoimmune disease.
Which treatments are used first for autoimmune brainstem encephalitis?
First-line options include high-dose intravenous methylprednisolone, IVIG, and plasma exchange. Doctors may use one treatment or combine treatments when disease is severe. Plasma exchange can remove recently given IVIG, so the two treatments must be carefully sequenced rather than given at the same time.
What happens if the first treatments do not improve my symptoms?
If symptoms remain severe or improvement is not sufficient, the medical team may consider rituximab, which lowers certain antibody-producing immune cells, or cyclophosphamide. The choice is individualized, especially when characteristic antibodies are absent, and requires careful monitoring for infection and other side effects.
How is the steroid taper handled after I leave the hospital?
Many patients transition to oral prednisone, which is gradually reduced over several weeks or months to lower the risk of inflammation returning. Never stop steroids suddenly or change the dose without specific instructions from your doctor.
What side effects will doctors watch for during treatment?
Steroids can raise blood sugar and blood pressure, disturb sleep or mood, weaken bones, and increase infection risk. IVIG, plasma exchange, and rituximab can cause infusion reactions or other complications, so clinicians monitor kidney function, hydration, blood pressure, electrolytes, blood counts, and infection signs. Screening for dormant infections such as hepatitis B may be needed before rituximab.
Can autoimmune brainstem encephalitis occur without a positive antibody test?
Yes, autoimmune brainstem encephalitis can still be considered when characteristic antibodies are not found. Doctors use the overall clinical picture, neurologic examination, spinal fluid and blood testing, imaging, and evaluation for infection rather than relying on one test alone.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current symptoms, what is our individualized plan for my immunotherapy, and how will we sequence the treatments?
  2. 2.If my swallowing or breathing does not improve, at what point will we reassess the diagnosis or consider escalation?
  3. 3.What is my specific 'taper' schedule for oral steroids after I leave the hospital, and what side effects should I watch for during that time?
  4. 4.How will you monitor me for infections while my immune system is being suppressed by these medications?
  5. 5.Are there any vaccinations or screenings (like for Hepatitis B or tuberculosis) I need before we start more intensive medications?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations.

    Dutra LA, Silva PVC, Ferreira JHF, et al.

    Arquivos de neuro-psiquiatria 2024; (82(7)):1-15 doi:10.1055/s-0044-1788586.

    PMID: 39089672
  2. 2

    Systematic Review and Meta-Analysis of the Clinical Features Associated With Seronegative Autoimmune Encephalitis.

    Di Cosmo L, Mulic-Al Bunni S, Goh Y, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2026; (13(2)):e200540 doi:10.1212/NXI.0000000000200540.

    PMID: 41499723
  3. 3

    Study on clinical features and factors related to long-term outcomes of antibody-negative autoimmune encephalitis.

    Han B, Dai Y, Peng J, et al.

    Annals of clinical and translational neurology 2024; (11(5)):1325-1337 doi:10.1002/acn3.52049.

    PMID: 38644648
  4. 4

    Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes.

    Lee WJ, Lee HS, Kim DY, et al.

    Brain : a journal of neurology 2022; (145(10)):3509-3521 doi:10.1093/brain/awac166.

    PMID: 35512357
  5. 5

    Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management.

    Abboud H, Probasco J, Irani SR, et al.

    Journal of neurology, neurosurgery, and psychiatry 2021; doi:10.1136/jnnp-2020-325302.

    PMID: 33649021
  6. 6

    Immunotherapies on autoimmune encephalitis.

    Lemmens CMC, Van Sonderen A, Titulaer MJ

    Handbook of clinical neurology 2026; (214()):269-289 doi:10.1016/B978-0-323-90887-0.00004-3.

    PMID: 41526139
  7. 7

    Combination Versus Monotherapy in Acute Anti-LGI1 Encephalitis: A Real-World Dose Optimization Analysis.

    Tan Y, Sun M, Liu Q, et al.

    Neuropsychopharmacology reports 2026; (46(2)):e70112 doi:10.1002/npr2.70112.

    PMID: 41858102
  8. 8

    The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis.

    Lee ST, Lee HS, Lee WJ, et al.

    Annals of clinical and translational neurology 2022; (9(5)):610-621 doi:10.1002/acn3.51540.

    PMID: 35315247
  9. 9

    Does the Use of Intravenous Immunoglobulin Improve Clinical Outcomes in Adults With Autoimmune Encephalitis? A Systematic Review.

    Kalra A, Mackay O, Thomas-Jones E, et al.

    Brain and behavior 2025; (15(5)):e70491 doi:10.1002/brb3.70491.

    PMID: 40356296
  10. 10

    Clinical efficacy of plasma exchange in patients with autoimmune encephalitis.

    Zhang Y, Huang HJ, Chen WB, et al.

    Annals of clinical and translational neurology 2021; (8(4)):763-773 doi:10.1002/acn3.51313.

    PMID: 33609012
  11. 11

    Immune therapy in autoimmune encephalitis: a systematic review.

    Nosadini M, Mohammad SS, Ramanathan S, et al.

    Expert review of neurotherapeutics 2015; (15(12)):1391-419 doi:10.1586/14737175.2015.1115720.

    PMID: 26559389
  12. 12

    Treatment Options in Refractory Autoimmune Encephalitis.

    Dinoto A, Ferrari S, Mariotto S

    CNS drugs 2022; (36(9)):919-931 doi:10.1007/s40263-022-00943-z.

    PMID: 35917105
  13. 13

    Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.

    Abboud H, Probasco JC, Irani S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2021; (92(7)):757-768 doi:10.1136/jnnp-2020-325300.

    PMID: 33649022
  14. 14

    An Update on the Treatment of Pediatric Autoimmune Encephalitis.

    Stingl C, Cardinale K, Van Mater H

    Current treatment options in rheumatology 2018; (4(1)):14-28 doi:10.1007/s40674-018-0089-z.

    PMID: 29780690
  15. 15

    Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort.

    Lee WJ, Lee ST, Byun JI, et al.

    Neurology 2016; (86(18)):1683-91 doi:10.1212/WNL.0000000000002635.

    PMID: 27037228
  16. 16

    Efficacy and safety of different oral prednisone tapering courses in adult anti-NMDAR encephalitis: A multicenter prospective cohort study.

    Cai L, Li G, Abdulaziz AT, et al.

    Epilepsia 2024; (65(11)):3199-3215 doi:10.1111/epi.18107.

    PMID: 39324872
  17. 17

    Autoimmune Encephalitis Misdiagnosis in Adults.

    Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al.

    JAMA neurology 2023; (80(1)):30-39 doi:10.1001/jamaneurol.2022.4251.

    PMID: 36441519
  18. 18

    Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children.

    Son MBF, Berbert L, Young C, et al.

    JAMA network open 2022; (5(11)):e2241622 doi:10.1001/jamanetworkopen.2022.41622.

    PMID: 36367723
  19. 19

    Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions.

    Watad A, Amital H, Shoenfeld Y

    Lupus 2017; (26(10)):1015-1022 doi:10.1177/0961203317696589.

    PMID: 28420062
  20. 20

    Clinical efficacy and immunomodulation of double-filtration plasmapheresis in autoimmune encephalitis: A prospective study highlighting the importance of timely initiation.

    Li H, Wang K, Li Q, et al.

    Journal of translational autoimmunity 2025; (11()):100318 doi:10.1016/j.jtauto.2025.100318.

    PMID: 41079906
  21. 21

    Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis.

    Nepal G, Shing YK, Yadav JK, et al.

    Acta neurologica Scandinavica 2020; (142(5)):449-459 doi:10.1111/ane.13291.

    PMID: 32484900
  22. 22

    Rituximab in the Intensive Care Unit: A Review of Indications and Clinical Considerations.

    Lincoln M, McGimsey T, O'Driscoll D

    Journal of intensive care medicine 2025; 8850666251409783 doi:10.1177/08850666251409783.

    PMID: 41451993
  23. 23

    Citrobacter freundii sepsis in an immunosuppressed patient with pemphigus vulgaris.

    Ferranti M, Tadiotto Cicogna G, Sattin A, Alaibac M

    BMJ case reports 2018; (11(1)) doi:10.1136/bcr-2018-227091.

    PMID: 30567283

This page is for informational purposes only and does not constitute medical advice. Your neurology and hospital team must tailor immune therapy, infection coverage, monitoring, and the steroid taper to your specific situation.

Get notified when new evidence is published on Non-specific autoimmune brainstem encephalitis without characteristic antibodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.